Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
The effects of hormone therapy on ischemia modified albumin and soluble CD40 ligand levels in obese surgical menopausal women
M.A. Osmanağaoğlu Osmanağaoğlu1,*, S.C. Karahan2, T. Aran1, S. Güven Güven1, A. Cora1, M. Kopuz2, H. Bozkaya1
Show Less
1
Karadeniz Technical University, Faculty of Medicine, Department of Obstetrics and Gynecology, Trabzon
2
Karadeniz Technical University, Faculty of Medicine, Department of Biochemistry, Trabzon (Turkey)
Clin. Exp. Obstet. Gynecol. 2013, 40(3), 389–392;
Published: 10 September 2013
Abstract
Purpose: To determine the effects of hormone therapy (HT) on ischemia modified albumin (IMA) and soluble (s)CD40 ligand in obese surgical menopausal women. Materials and Methods: A total of 52 obese surgical menopausal women with a body mass index (BMI) > 30 kg/m2 were admitted to the study. Twenty-seven women received estradiol hemihydrate two mg and 25 did not receive any menopausal therapy. At baseline and after three and six months of treatment, IMA and sCD40 ligand levels were measured. Results: There were no significant differences among the groups for any variables at baseline. No difference in change in the serum sCD40L levels was found in obese surgical menopausal women after three and six months of HT. Serum IMA levels were statistically lowered in obese women with HT after six months of treatment. Conclusion: HT may have a beneficial reduction in IMA levels in obese surgical menopausal women.
Keywords
Hormone therapy
sCD40 ligand
Ischemia modified albumin
Body mass index
Surgical menopause